Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer

BMC Surg. 2021 Jan 6;21(1):8. doi: 10.1186/s12893-020-00976-5.


Background: Decreased mean platelet volume (MPV) predicts poor prognosis in some cancers. However, its significance as a prognostic indicator in pancreatic cancer (PC) remains unclear.

Methods: A total of 91 PC patients who underwent pancreatectomy were included in this study. MPV and serum carbohydrate antigen 19-9 (CA19-9) were measured within 1 week before surgery.

Results: We divided patients into MPVhigh (≥ 8.65; n = 40), MPVlow (< 8.65; n = 51), CA19-9high (≥ 66.3; n = 47), and CA19-9low (< 66.3; n = 44) groups based on the optimal cut-off values determined from receiver operating characteristic curve analysis. The 5-year overall survival (OS) rates were significantly lower in the MPVlow than in the MPVhigh group (16.9% and 56.3%, respectively; P = 0.0038), and the 5-year disease-specific survival (DSS) rates in the MPVlow group and MPVhigh group were 20.5% and 62.2%, respectively (P = 0.0031). Multivariate analysis identified MPV as an independent prognostic indicator for both OS and DSS. The patients were then divided into groups A (MPVhigh and CA19-9low), B (MPVhigh and CA19-9high), C (MPVlow and CA19-9low), and D (MPVlow and CA19-9high), with 5-year OS rates of 73.2%, 40.4%, 25.8%, and 10.3%, respectively (P = 0.0002), and 5-year DSS rates of 80.8%, 44.9%, 27.3%, and 16.4%, respectively (P = 0.0003).

Conclusions: Classification based on MPV and CA19-9 might be useful for predicting long-term outcomes in patients with PC.

Keywords: Carbohydrate antigen 19-9; Mean platelet volume; Pancreatic cancer; Prognosis.

MeSH terms

  • Aged
  • CA-19-9 Antigen
  • Female
  • Humans
  • Male
  • Mean Platelet Volume*
  • Pancreatic Neoplasms* / blood
  • Pancreatic Neoplasms* / surgery
  • Prognosis
  • Retrospective Studies


  • CA-19-9 Antigen